International consensus statement on attention-deficit/hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. American Academy of Pediatrics Subcommittee on Attention-Deficit/Hyperactivity Disorder Committee on Quality Improvement. Eur Neuropsychopharmacol 2003 Aug 13(4): 297вЂ“304Д¬linical practice guideline: treatment of the school-aged child with attentiondeficit/hyperactivity disorder. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. в–І Adverse events with lisdexamfetamine were, in general, mild to moderate in severity and consistent with those commonly reported with amphetamine.Д«uitelaar JK, Montgomery SA, van Zwieten-Boot BJ. в–І In two well designed trials in children aged 6вЂ“12 years with attention-deficit hyperactivity disorder (ADHD), the efficacy of lisdexamfetamine was superior to that of placebo in improving symptoms associated with ADHD. The pharmacokinetics of lisdexamfetamine suggest a reduced potential for abuse. в–І Through rate-limited hydrolysis in the body, l-lysine is cleaved, gradually releasing pharmacologically active d-amphetamine. в–І Ina well designed pharmacodynamic study in adult stimulant abusers, 50 or 100mg doses of oral lisdexamfetamine had less likability than d-amphetamine 40mg, suggesting a reduced abuse potential.

After oral ingestion, lisdexamfetamine is hydrolyzed to l-lysine, a naturally occurring essential amino acid, and active d-amphetamine, which is responsible for the activity of the drug. в–І Lisdexamfetamine is a therapeutically inactive molecule. Lisdexamfetamine is approved in the US for the treatment of attention-deficit hyperactivity disorder in children aged 6вЂ“12 years. в–І Lisdexamfetamine is an amphetamine prodrug, comprising an l-lysine amino acid covalently bonded to dextroamphetamine ( d-amphetamine).

Amphetamine adhd